Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT03208465

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03208465
Other papers using this trial's data
  • Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease Nuclear medicine communications, 2021-09-01 DOI, PubMed 34397987

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03208465. Randomized; no masking; primary purpose treatment. Start 2017-08-07 (actual); primary completion 2019-08-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
Acronym
ELITE
Condition
Diabetes Mellitus
Condition
Coronary Disease
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Sitagliptin
Lead sponsor
CHEOL WHAN LEE, M.D., Ph.D (class: other)

Record details

Record id
cardio:ct-nct03208465
Content hash
937ecf69ab1464f6c2aadcf5a3dd87407915fc92c0591bdaba3ae8a94fa93de0